INTRODUCTION: Longitudinal studies have reported that patients with idiopathic rapid eye movement sleep behavior disorder (IRBD) have an increased risk of developing synucleinopathies, such as Parkinson's disease and dementia with Lewy bodies (DLB). Clinical trials of disease-modifying therapies for IRBD patients require suitable biomarkers that can predict the short-term onset of neurodegenerative dementia. METHODS: We retrospectively examined if easy Z-score imaging system-specific volume-of-interest analysis (SVA) using brain perfusion single-photon emission computed tomography (SPECT) imaging or the cingulate island sign score can predict the short-term development of neurodegenerative dementia in 30 patients with IRBD. RESULTS: Ten patients (33.3%) who exceeded the thresholds for three indicators (severity, extent, and ratio) were included in an SVA-positive group, while 20 (66.7%) were included in an SVA-negative group. Nine (30.0%) IRBD patients had phenoconversion, of which eight had DLB and one had Parkinson's disease with dementia. In Kaplan-Meier analysis, patients in the SVA-positive group converted to neurodegenerative dementia in a significantly shorter period of time compared to patients in the SVA-negative group. CONCLUSIONS: These data suggest that SVA-positive IRBD patients have an increased short-term risk of developing neurodegenerative dementia.
INTRODUCTION: Longitudinal studies have reported that patients with idiopathic rapid eye movement sleep behavior disorder (IRBD) have an increased risk of developing synucleinopathies, such as Parkinson's disease and dementia with Lewy bodies (DLB). Clinical trials of disease-modifying therapies for IRBD patients require suitable biomarkers that can predict the short-term onset of neurodegenerative dementia. METHODS: We retrospectively examined if easy Z-score imaging system-specific volume-of-interest analysis (SVA) using brain perfusion single-photon emission computed tomography (SPECT) imaging or the cingulate island sign score can predict the short-term development of neurodegenerative dementia in 30 patients with IRBD. RESULTS: Ten patients (33.3%) who exceeded the thresholds for three indicators (severity, extent, and ratio) were included in an SVA-positive group, while 20 (66.7%) were included in an SVA-negative group. Nine (30.0%) IRBD patients had phenoconversion, of which eight had DLB and one had Parkinson's disease with dementia. In Kaplan-Meier analysis, patients in the SVA-positive group converted to neurodegenerative dementia in a significantly shorter period of time compared to patients in the SVA-negative group. CONCLUSIONS: These data suggest that SVA-positive IRBD patients have an increased short-term risk of developing neurodegenerative dementia.
Authors: Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak Journal: Neurobiol Aging Date: 2003 Mar-Apr Impact factor: 4.673
Authors: Brendon P Boot; Bradley F Boeve; Rosebud O Roberts; Tanis J Ferman; Yonas E Geda; V Shane Pankratz; Robert J Ivnik; Glenn E Smith; Eric McDade; Teresa J H Christianson; David S Knopman; Eric G Tangalos; Michael H Silber; Ronald C Petersen Journal: Ann Neurol Date: 2012-01 Impact factor: 10.422
Authors: Randy L Buckner; Jorge Sepulcre; Tanveer Talukdar; Fenna M Krienen; Hesheng Liu; Trey Hedden; Jessica R Andrews-Hanna; Reisa A Sperling; Keith A Johnson Journal: J Neurosci Date: 2009-02-11 Impact factor: 6.167
Authors: M D Ikonomovic; W E Klunk; E E Abrahamson; J Wuu; C A Mathis; S W Scheff; E J Mufson; S T DeKosky Journal: Neurology Date: 2011-06-22 Impact factor: 9.910
Authors: K Lobotesis; J D Fenwick; A Phipps; A Ryman; A Swann; C Ballard; I G McKeith; J T O'Brien Journal: Neurology Date: 2001-03-13 Impact factor: 9.910
Authors: David J Irwin; Murray Grossman; Daniel Weintraub; Howard I Hurtig; John E Duda; Sharon X Xie; Edward B Lee; Vivianna M Van Deerlin; Oscar L Lopez; Julia K Kofler; Peter T Nelson; Gregory A Jicha; Randy Woltjer; Joseph F Quinn; Jeffery Kaye; James B Leverenz; Debby Tsuang; Katelan Longfellow; Dora Yearout; Walter Kukull; C Dirk Keene; Thomas J Montine; Cyrus P Zabetian; John Q Trojanowski Journal: Lancet Neurol Date: 2017-01 Impact factor: 44.182
Authors: Yvette I Sheline; Marcus E Raichle; Abraham Z Snyder; John C Morris; Denise Head; Suzhi Wang; Mark A Mintun Journal: Biol Psychiatry Date: 2009-10-14 Impact factor: 13.382